These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32815211)

  • 1. Absence of toxic epidermal necrolysis recurrence with pembrolizumab re-challenge in a patient with a positive lymphocyte transformation test.
    Kawada M; Nobeyama Y; Goto Y; Nakama K; Yamazaki N; Asahina A
    J Dermatol; 2020 Dec; 47(12):e424-e425. PubMed ID: 32815211
    [No Abstract]   [Full Text] [Related]  

  • 2. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of drug causality in Stevens-Johnson syndrome/toxic epidermal necrolysis: Concordance between lymphocyte transformation test and ALDEN.
    Bellón T; Rodríguez-Martín S; Cabañas R; Ramírez E; Lerma V; González-Herrada C; González O; Sendagorta E; Fiandor A; de Abajo FJ;
    Allergy; 2020 Apr; 75(4):956-959. PubMed ID: 31557316
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
    Hwang A; Iskandar A; Dasanu CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Reactivity Between Carbonic Anhydrase Inhibitor Confirmed by Lymphocyte Transformation Test: A Case of Methazolamide-Induced Toxic Epidermal Necrolysis.
    Sohn KH; Kim SH; Kang HR
    J Investig Allergol Clin Immunol; 2021 Oct; 31(5):455-456. PubMed ID: 33439124
    [No Abstract]   [Full Text] [Related]  

  • 7. CD8
    Jee YK; Kim S; Lee JM; Park HS; Kim SH
    Clin Exp Allergy; 2017 Jul; 47(7):972-974. PubMed ID: 28295713
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
    Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC;
    Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
    Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
    Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
    [No Abstract]   [Full Text] [Related]  

  • 10. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
    Robinson S; Saleh J; Curry J; Mudaliar K
    Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.
    Lomax AJ; McQuillan PIA; Hall A; McArthur GA
    Intern Med J; 2019 Aug; 49(8):1051-1053. PubMed ID: 31387152
    [No Abstract]   [Full Text] [Related]  

  • 12. Warfarin-induced toxic epidermal necrolysis after mitral valve replacement.
    Kuroda T; Yokoyama Y; Yamada M; Yuhara S; Hasegawa H; Yokote J
    Asian Cardiovasc Thorac Ann; 2020 Nov; 28(9):601-603. PubMed ID: 32787441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erythema multiforme exudativum, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome) and their interrelationship].
    Kalamkarian AA; Samsonov VA
    Vestn Dermatol Venerol; 1980 Mar; (3):36-42. PubMed ID: 6990649
    [No Abstract]   [Full Text] [Related]  

  • 14. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review.
    Gerull R; Nelle M; Schaible T
    Crit Care Med; 2011 Jun; 39(6):1521-32. PubMed ID: 21358399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test.
    Porebski G; Pecaric-Petkovic T; Groux-Keller M; Bosak M; Kawabata TT; Pichler WJ
    Clin Exp Allergy; 2013 Sep; 43(9):1027-37. PubMed ID: 23957338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults.
    Lee HY; Tharmotharampillai T; Pang SM
    Int J Dermatol; 2017 Apr; 56(4):e78-e79. PubMed ID: 27868186
    [No Abstract]   [Full Text] [Related]  

  • 19. [Toxic epidermal necrolysis (syndrome Lyell) versus Stevens-Johnson syndrome].
    Jezierska-Krupa B; Hyla-Klekot L
    Pediatr Pol; 1996 Jul; 71(7):615-20. PubMed ID: 8803466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.
    Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J
    Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.